Nomura Holdings Inc ADR (NMR)
Official siteFINANCIAL SERVICES • CAPITAL MARKETS • NYSE
Market Cap: $28.35B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nomura Holdings Inc ADR (NMR) P/E Ratio & Valuation Multiples
Nomura Holdings Inc ADR (NMR) trades at 10.8x trailing earnings and 1.0x sales. Its P/S of 1.0x is above its 5-year median of 0.8x. Its forward P/E is 15.4x. The median P/E across 10 similar companies is 17.8x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 29.9% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 10.8x |
| Forward P/E | 15.4x |
| Price to sales | 1.0x |
| Price to book | 1.2x |
| EV/EBITDA | 25.9x |
| PEG | 0.8 |
| FCF yield | -54.5% |
Historical Medians
Against its 10-year medians, its P/S is 11.1% above 0.9x and its P/B is 71.4% above 0.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.0x | 0.8x | 0.9x |
| P/B | 1.2x | 0.8x | 0.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.6x in 2024 to 1.5x in 2016.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $8.39 | 0.9x | 1.1x |
| 2024 | $5.79 | 0.6x | 0.8x |
| 2023 | $4.51 | 0.6x | 0.6x |
| 2022 | $3.75 | 0.8x | 0.5x |
| 2021 | $4.33 | 1.2x | 0.6x |
| 2020 | $5.33 | 1.1x | 0.6x |
| 2019 | $5.16 | 1.0x | 0.7x |
| 2018 | $3.72 | 0.8x | 0.5x |
| 2017 | $5.82 | 1.3x | 0.8x |
| 2016 | $5.90 | 1.5x | 0.9x |
P/E history is shown only for companies that report in US dollars.
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NMR
What is NMR's forward P/E ratio?
Nomura Holdings Inc ADR has a forward P/E ratio of 15.4x.
Is NMR stock overvalued?
GNG's valuation label for NMR is Overvalued. Its P/E of 10.8x compares with a median of 17.8x across 10 similar companies.
What is NMR's price to sales ratio?
Nomura Holdings Inc ADR has a price to sales ratio of 1.0x.
What is NMR's PEG ratio?
Nomura Holdings Inc ADR has a PEG ratio of 0.8.
NMR pages: Overview, Dividends, Financials, Valuation, Competitors